Medicina
Departamento
Ghent University
Gante, BélgicaPublicaciones en colaboración con investigadores/as de Ghent University (46)
2024
2023
-
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
European Urology
-
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
European Journal of Cancer
-
Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification
Mayo Clinic Proceedings
-
Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification
Kidney International, Vol. 104, Núm. 6, pp. 1092-1102
2022
-
A Systematic Review of the Current Evidence from Randomised Controlled Trials on the Impact of Medication Optimisation or Pharmacological Interventions on Quantitative Measures of Cognitive Function in Geriatric Patients
Drugs and Aging, Vol. 39, Núm. 11, pp. 863-874
-
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
ESMO Open, Vol. 7, Núm. 5
-
Poor timing and failure of source control are risk factors for mortality in critically ill patients with secondary peritonitis
Intensive Care Medicine, Vol. 48, Núm. 11, pp. 1593-1606
2021
-
Correction to: Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty: a systematic review of randomized controlled trials (European Journal of Clinical Pharmacology, (2021), 77, 1, (1-12), 10.1007/s00228-020-02951-8)
European Journal of Clinical Pharmacology
-
Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty: a systematic review of randomized controlled trials
European Journal of Clinical Pharmacology, Vol. 77, Núm. 1
-
Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study
Journal of Allergy and Clinical Immunology, Vol. 147, Núm. 1, pp. 60-71
-
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 18, pp. 1959-1970
-
Management of anaphylaxis due to COVID-19 vaccines in the elderly
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 10, pp. 2952-2964
-
The burden of systemic sclerosis in Switzerland - the Swiss systemic sclerosis EUSTAR cohort
Swiss medical weekly, Vol. 151, pp. w20528
2020
-
Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))
Atherosclerosis
-
Erratum to “2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))
Atherosclerosis
-
Racial differences in systemic sclerosis disease presentation: A European Scleroderma Trials and Research group study
Rheumatology (United Kingdom), Vol. 59, Núm. 7, pp. 1684-1694
-
Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1
Science Translational Medicine, Vol. 12, Núm. 542
2019
-
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
Atherosclerosis, Vol. 290, pp. 140-205
-
Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report
Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2109-2119